The Manufacturers Life Insurance Company Has $918,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

The Manufacturers Life Insurance Company cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 47,704 shares of the company’s stock after selling 964 shares during the period. The Manufacturers Life Insurance Company owned about 0.06% of Syndax Pharmaceuticals worth $918,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of SNDX. Simplify Asset Management Inc. increased its holdings in Syndax Pharmaceuticals by 62.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock worth $2,352,000 after purchasing an additional 46,992 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Syndax Pharmaceuticals by 54.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 428,949 shares of the company’s stock worth $8,806,000 after buying an additional 151,021 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Syndax Pharmaceuticals by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock worth $13,397,000 after acquiring an additional 41,458 shares during the last quarter. Bank of New York Mellon Corp increased its position in Syndax Pharmaceuticals by 18.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 291,826 shares of the company’s stock valued at $5,991,000 after acquiring an additional 46,463 shares during the period. Finally, First Turn Management LLC raised its stake in shares of Syndax Pharmaceuticals by 85.4% during the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after acquiring an additional 546,776 shares during the last quarter.

Syndax Pharmaceuticals Stock Down 5.3 %

NASDAQ:SNDX opened at $13.47 on Friday. Syndax Pharmaceuticals, Inc. has a 52 week low of $13.32 and a 52 week high of $25.34. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -3.71 and a beta of 0.86. The company’s 50 day moving average price is $17.91 and its 200-day moving average price is $19.51.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. As a group, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, November 21st. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target on the stock. Barclays lifted their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. Finally, Stifel Nicolaus boosted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.64.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).